Background: The role of patent foramen ovale is a field of debate and current publications have increasing controversies about the patients’ management in young undetermined stroke. Work up with echocardiography and transcranial Doppler (TCD) can aid the decision with better anatomical and functional characterization of right-to-left shunt (RLS). Medical and interventional strategy may benefit from this information. Summary: a group of experts from the Latin American participants of the Neurosonology Research Group (NSRG) of World Federation of Neurology created a task force to review literature and describe the better methodology of contrast TCD (c-TCD). All signatories of the present consensus statement have published at least one study on TCD as an author or co-author in an indexed journal. Two meetings were held while the consensus statement was being drafted, during which controversial issues were discussed and voted on by the statement signatories. The statement paper was reviewed and approved by the Executive Committee of the NSRG of the World Federation of Neurology. The main objective of this consensus statement is to establish a standardization of the c-TCD technique and its interpretation, in order to improve the informative quality of the method, resulting in expanding the application of TCD in the clinical setting. These recommendations optimize the comparison of different diagnostic methods and encourage the use of c-TCD for RLS screening and complementary diagnosis in multicenter studies.

Keywords:
Transcranial Doppler, Contrast-transcranial Doppler, Patent foramen ovale, Right to left shunt, Statement
1.
Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, et al.; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
N Engl J Med
. 2017 Sep;377(11):1011–21.
2.
Saver JL, Carroll JD, Thaler DE, Smalling RW, MacDonald LA, Marks DS, et al.; RESPECT Investigators. Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke.
N Engl J Med
. 2017 Sep;377(11):1022–32.
3.
Søndergaard L, Kasner SE, Rhodes JF, Andersen G, Iversen HK, Nielsen-Kudsk JE, et al.; Gore REDUCE Clinical Study Investigators. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke.
N Engl J Med
. 2017 Sep;377(11):1033–42.
4.
Dao CN, Tobis JM. PFO and paradoxical embolism producing events other than stroke.
Catheter Cardiovasc Interv
. 2011 May;77(6):903–9.
5.
Riaz IB, Dhoble A, Mizyed A, Hsu CH, Husnain M, Lee JZ, et al. Transcatheter patent foramen ovale closure versus medical therapy for cryptogenic stroke: a meta-analysis of randomized clinical trials.
BMC Cardiovasc Disord
. 2013 Dec;13(1):116.
6.
Bang OY, Lee MJ, Ryoo S, Kim SJ, Kim JW. Patent Foramen Ovale and Stroke-­Current Status.
J Stroke
. 2015 Sep;17(3):229–37.
7.
Rigatelli G, Aggio S, Cardaioli P, Braggion G, Giordan M, Dell’avvocata F, et al. Left atrial dysfunction in patients with patent foramen ovale and atrial septal aneurysm: an alternative concurrent mechanism for arterial embolism?
JACC Cardiovasc Interv
. 2009 Jul;2(7):655–62.
8.
Song BG, Park SW, Lee SC, Choi JO, Park SJ, Chang SA, et al. Real-time 3D TEE for multiperforated interatrial septum.
JACC Cardiovasc Imaging
. 2010 Nov;3(11):1199.
9.
Pushparajah K, Miller OI, Simpson JM. 3D echocardiography of the atrial septum: anatomical features and landmarks for the echocardiographer.
JACC Cardiovasc Imaging
. 2010 Sep;3(9):981–4.
10.
Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Wolf ME, Hennerici MG. The ASCOD phenotyping of ischemic stroke (Updated ASCO Phenotyping).
Cerebrovasc Dis
. 2013;36(1):1–5.
11.
Furlan AJ, Reisman M, Massaro J, Mauri L, Adams H, Albers GW, et al.; CLOSURE I Investigators. Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
N Engl J Med
. 2012 Mar;366(11):991–9.
12.
Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, et al.; PC Trial Investigators. Percutaneous closure of patent foramen ovale in cryptogenic embolism.
N Engl J Med
. 2013 Mar;368(12):1083–91.
13.
Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, et al.; RESPECT Investigators. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
N Engl J Med
. 2013 Mar;368(12):1092–100.
14.
Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ, et al.; Cryptogenic Stroke/ESUS International Working Group. Embolic strokes of undetermined source: the case for a new clinical construct.
Lancet Neurol
. 2014 Apr;13(4):429–38.
15.
Kent DM, Ruthazer R, Weimar C, Mas JL, Serena J, Homma S, et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.
Neurology
. 2013 Aug;81(7):619–25.
16.
Rigatelli G, Dell’Avvocata F, Giordan M, Braggion G, Aggio S, Chinaglia M, et al. Embolic implications of combined risk factors in patients with patent foramen ovale (the CARPE criteria): consideration for primary prevention closure?
J Interv Cardiol
. 2009 Aug;22(4):398–403.
17.
Ropper AH. Tipping Point for Patent Foramen Ovale Closure.
N Engl J Med
. 2017 Sep;377(11):1093–5.
18.
Farb A, Ibrahim NG, Zuckerman BD. Patent Foramen Ovale after Cryptogenic Stroke - Assessing the Evidence for Closure.
N Engl J Med
. 2017 Sep;377(11):1006–9.
19.
Zhang XL, Kang LN, Wang L, Xu B. Percutaneous closure versus medical therapy for stroke with patent foramen Ovale: a systematic review and meta-analysis.
BMC Cardiovasc Disord
. 2018 Mar;18(1):45.
20.
Rigatelli G, Dell’avvocata F, Daggubati R, Dung HT, Nghia NT, Nanjiundappa A, et al. Impact of interatrial septum anatomic features on short- and long-term outcomes after transcatheter closure of patent foramen ovale: single device type versus anatomic-driven device selection strategy.
J Interv Cardiol
. 2013 Aug;26(4):392–8.
21.
Cooke JC, Gelman JS, Harper RW. Chiari network entanglement and herniation into the left atrium by an atrial septal defect occluder device.
J Am Soc Echocardiogr
. 1999 Jul;12(7):601–3.
22.
Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, et al.; NAVIGATE ESUS Investigators. Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.
Lancet Neurol
. 2018 Dec;17(12):1053–60.
23.
Mazzucco S, Li L, Binney L, Rothwell PM; Oxford Vascular Study Phenotyped Cohort. Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis.
Lancet Neurol
. 2018 Jul;17(7):609–17.
24.
Souteyrand G, Motreff P, Lusson JR, Rodriguez R, Geoffroy E, Dauphin C, et al. Comparison of transthoracic echocardiography using second harmonic imaging, transcranial Doppler and transesophageal echocardiography for the detection of patent foramen ovale in stroke patients.
Eur J Echocardiogr
. 2006 Mar;7(2):147–54.
25.
Silvestry FE, Cohen MS, Armsby LB, Burkule NJ, Fleishman CE, Hijazi ZM, et al.; American Society of Echocardiography; Society for Cardiac Angiography and Interventions. Guidelines for the Echocardiographic Assessment of Atrial Septal Defect and Patent Foramen Ovale: From the American Society of Echocardiography and Society for Cardiac Angiography and Interventions.
J Am Soc Echocardiogr
. 2015 Aug;28(8):910–58.
26.
Homma S, Sacco RL. Patent foramen ovale and stroke.
Circulation
. 2005 Aug;112(7):1063–72.
27.
Agmon Y, Khandheria BK, Meissner I, Gentile F, Whisnant JP, Sicks JD, et al. Frequency of atrial septal aneurysms in patients with cerebral ischemic events.
Circulation
. 1999 Apr;99(15):1942–4.
28.
Giannopoulos A, Gavras C, Sarioglou S, Agathagelou F, Kassapoglou I, Athanassiadou F. Atrial septal aneurysms in childhood: prevalence, classification, and concurrent abnormalities.
Cardiol Young
. 2014 Jun;24(3):453–8.
29.
Tanaka J, Izumo M, Fukuoka Y, Saitoh T, Harada K, Harada K, et al. Comparison of two-dimensional versus real-time three-dimensional transesophageal echocardiography for evaluation of patent foramen ovale morphology.
Am J Cardiol
. 2013 Apr;111(7):1052–6.
30.
Rana BS, Shapiro LM, McCarthy KP, Ho SY. Three-dimensional imaging of the atrial septum and patent foramen ovale anatomy: defining the morphological phenotypes of patent foramen ovale.
Eur J Echocardiogr
. 2010 Dec;11(10):i19–25.
31.
Lange MC, Zétola VF, de Souza AM, Piovesan EJ, Muzzio JA, Germiniani FM, et al. Transcranial Doppler for patent foramen ovale screening: is there a good correlation with transesophageal echocardiography?
Arq Neuropsiquiatr
. 2008 Dec;66(4):785–9.
32.
Sloan MA, Alexandrov AV, Tegeler CH, Spencer MP, Caplan LR, Feldmann E, et al. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Neurology
. 2004 May;62(9):1468–81.
33.
Caputi L, Carriero MR, Falcone C, Parati E, Piotti P, Materazzo C, et al. Transcranial Doppler and transesophageal echocardiography: comparison of both techniques and prospective clinical relevance of transcranial Doppler in patent foramen ovale detection.
J Stroke Cerebrovasc Dis
. 2009 Sep-Oct;18(5):343–8.
34.
Lange MC, Zétola VF, deSouza AM, Novak FM, Piovesan EJ, Werneck LC. Intracranial embolism characteristics in PFO patients: a comparison between positive and negative PFO by transesophageal echocardiography: the rule of nine.
J Neurol Sci
. 2010 Jun;293(1-2):106–9.
35.
Mojadidi MK, Roberts SC, Winoker JS, Romero J, Goodman-Meza D, Gevorgyan R, et al. Accuracy of transcranial Doppler for the diagnosis of intracardiac right-to-left shunt: a bivariate meta-analysis of prospective studies.
JACC Cardiovasc Imaging
. 2014 Mar;7(3):236–50.
36.
Schneider B, Hofmann T, Justen MH, Meinertz T. Chiari’s network: normal anatomic variant or risk factor for arterial embolic events?
J Am Coll Cardiol
. 1995 Jul;26(1):203–10.
37.
Schuchlenz HW, Saurer G, Weihs W, Rehak P. Persisting eustachian valve in adults: relation to patent foramen ovale and cerebrovascular events.
J Am Soc Echocardiogr
. 2004 Mar;17(3):231–3.
38.
Scaffa R, Spaziani C, Leporace M, Leonetti S, Di Roma M, Gaspardone A, et al. Voluminous atrial septal aneurysm may mask a large double atrial septal defect.
Ann Thorac Surg
. 2012 Feb;93(2):e41.
39.
Marriott K, Manins V, Forshaw A, Wright J, Pascoe R. Detection of right-to-left atrial communication using agitated saline contrast imaging: experience with 1162 patients and recommendations for echocardiography.
J Am Soc Echocardiogr
. 2013 Jan;26(1):96–102.
40.
Mas JL, Arquizan C, Lamy C, Zuber M, Cabanes L, Derumeaux G, et al.; Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
N Engl J Med
. 2001 Dec;345(24):1740–6.
41.
Di Tullio M, Sacco RL, Venketasubramanian N, Sherman D, Mohr JP, Homma S. Comparison of diagnostic techniques for the detection of a patent foramen ovale in stroke patients.
Stroke
. 1993 Jul;24(7):1020–4.
42.
Attaran RR, Ata I, Kudithipudi V, Foster L, Sorrell VL. Protocol for optimal detection and exclusion of a patent foramen ovale using transthoracic echocardiography with agitated saline microbubbles.
Echocardiography
. 2006 Aug;23(7):616–22.
43.
Johansson MC, Helgason H, Dellborg M, Eriksson P. Sensitivity for detection of patent foramen ovale increased with increasing number of contrast injections: a descriptive study with contrast transesophageal echocardiography.
J Am Soc Echocardiogr
. 2008 May;21(5):419–24.
44.
Fan S, Nagai T, Luo H, Atar S, Naqvi T, Birnbaum Y, et al. Superiority of the combination of blood and agitated saline for routine contrast enhancement.
J Am Soc Echocardiogr
. 1999 Feb;12(2):94–8.
45.
Woods TD, Patel A. A critical review of patent foramen ovale detection using saline contrast echocardiography: when bubbles lie.
J Am Soc Echocardiogr
. 2006 Feb;19(2):215–22.
46.
Johansson MC, Eriksson P, Guron CW, Dellborg M. Pitfalls in diagnosing PFO: characteristics of false-negative contrast injections during transesophageal echocardiography in patients with patent foramen ovales.
J Am Soc Echocardiogr
. 2010 Nov;23(11):1136–42.
47.
Lange MC, Zétola VF, Piovesan ÉJ, Werneck LC. Saline versus saline with blood as a contrast agent for right-to-left shunt diagnosis by transcranial Doppler: is there a significant difference?
J Neuroimaging
. 2012 Jan;22(1):17–20.
48.
Jauss M, Zanette E. Detection of right-to-left shunt with ultrasound contrast agent and transcranial Doppler sonography.
Cerebrovasc Dis
. 2000 Nov-Dec;10(6):490–6.
49.
Ringelstein EB, Droste DW, Babikian VL, Evans DH, Grosset DG, Kaps M, et al.; International Consensus Group on Microembolus Detection. Consensus on microembolus detection by TCD.
Stroke
. 1998 Mar;29(3):725–9.
50.
Markus H. Importance of time-window overlap in the detection and analysis of embolic signals.
Stroke
. 1995 Nov;26(11):2044–7.
51.
Shi WT, Forsberg F, Raichlen JS, Needleman L, Goldberg BB. Pressure dependence of subharmonic signals from contrast microbubbles.
Ultrasound Med Biol
. 1999 Feb;25(2):275–83.
52.
Gentile M, De Vito A, Azzini C, Tamborino C, Casetta I. Adding blood to agitated saline significantly improves detection of right-to-left shunt by contrast-transcranial color-coded duplex sonography.
Ultrasound Med Biol
. 2014 Nov;40(11):2637–41.
53.
Puledda F, Toscano M, Pieroni A, Veneroso G, Di Piero V, Vicenzini E. Right-to-left shunt detection sensitivity with air-saline and air-succinil gelatin transcranial Doppler.
Int J Stroke
. 2016 Feb;11(2):229–38.
54.
Lange MC, Zétola VF, Piovesan EJ, Werneck LC. Valsalva maneuver procedures in the diagnosis of right-to-left shunt by contrast-enhanced transcranial doppler using agitated saline solution with blood as a contrast agent.
Arq Neuropsiquiatr
. 2010 Jun;68(3):410–3.
55.
Guo YZ, Gao YS, Guo ZN, Niu PP, Yang Y, Xing YQ. Comparison of Different Methods of Valsalva Maneuver for Right-to-left Shunt Detection by Contrast-Enhanced Transcranial Doppler.
Ultrasound Med Biol
. 2016 May;42(5):1124–9.
56.
Rodrigues AC, Picard MH, Carbone A, Arruda AL, Flores T, Klohn J, et al. Importance of adequately performed Valsalva maneuver to detect patent foramen ovale during transesophageal echocardiography.
J Am Soc Echocardiogr
. 2013 Nov;26(11):1337–43.
57.
Tobe J, Bogiatzi C, Munoz C, Tamayo A, Spence JD. Transcranial Doppler is Complementary to Echocardiography for Detection and Risk Stratification of Patent Foramen Ovale.
Can J Cardiol
. 2016 Aug;32(8):986.e9–16.
58.
Rigatelli G, Dell’Avvocata F, Cardaioli P, Giordan M, Braggion G, Aggio S, et al. Permanent right-to-left shunt is the key factor in managing patent foramen ovale.
J Am Coll Cardiol
. 2011 Nov;58(21):2257–61.
59.
González-Alujas T, Evangelista A, Santamarina E, Rubiera M, Gómez-Bosch Z, Rodríguez-Palomares JF, et al. Diagnosis and quantification of patent foramen ovale. Which is the reference technique? Simultaneous study with transcranial Doppler, transthoracic and transesophageal echocardiography.
Rev Esp Cardiol
. 2011 Feb;64(2):133–9.
60.
Benjamin S. Wessler, David M. Kent, David E. Thaler, Robin Ruthazer, Jennifer S. Lutz, Joaquín Serena. The RoPE Score and Right-to-Left Shunt Severity by Transcranial Doppler in the CODICIA Study.
Cerebrovasc Dis
. 2015;40(0):52–8.
61.
D’Andrea A, Conte M, Riegler L, Scarafile R, Cocchia R, Pezzullo E, et al. Transcranial Doppler Ultrasound: Incremental Diagnostic Role in Cryptogenic Stroke Part II.
J Cardiovasc Echogr
. 2016 Jul-Sep;26(3):71–7.
62.
Lao AY, Sharma VK, Tsivgoulis G, Frey JL, Malkoff MD, Navarro JC, et al. Detection of right-to-left shunts: comparison between the International Consensus and Spencer Logarithmic Scale criteria.
J Neuroimaging
. 2008 Oct;18(4):402–6.
63.
Guchlerner M, Kardos P, Liss-Koch E, Franke J, Wunderlich N, Bertog S, et al. PFO and right-to-left shunting in patients with obstructive sleep apnea.
J Clin Sleep Med
. 2012 Aug;8(4):375–80.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.